Heat Biologics Stock Price - HTBX

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type
Heat Biologics Inc HTBX NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.005 -0.88% 0.56 0.5688 0.55 0.5599 0.565 16:50:20
Bid Price Ask Price Spread Spread % News
0.5502 0.57 0.0198 3.47% 1 -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
80 30,068 $ 0.562648 $ 16,918 318,638 0.51 - 2.24
Last Trade Time Type Quantity Stock Price Currency
17:06:23 6 $ 0.5502 USD

Heat Biologics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 19.08M 34.07M $ -15.73M -1.29 - 31.65M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 7.10%

more financials information »

Heat Biologics News

Loading Messages....

Latest HTBX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical HTBX Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week0.55630.60.5120.558083k0.00370.67%
1 Month0.57390.83580.510.6425360k-0.0139-2.42%
3 Months0.7691.150.510.7331356k-0.209-27.18%
6 Months1.351.860.511.0902413k-0.79-58.52%
1 Year1.892.240.511.2559375k-1.33-70.37%
3 Years15.333.50.518.0416815k-14.74-96.34%
5 Years58.31090.519.7495622k-57.74-99.04%

Heat Biologics Description

Heat Biologics Inc is a US-based immuno-oncology company. It is engaged in developing therapies which activate a patient's immune system against cancer utilizing an engineered form of gp96. The group's T cell-stimulating therapeutic vaccine platform technologies, Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT), form the basis of its product candidates. Through ImPACT, it developed product candidates consisting of live, genetically-modified, irradiated human cancer cells which secrete tumor-associated antigens together with an immune response stimulator called gp96. Through ComPACT, the firm engineered product candidates that incorporate ligand fusion proteins targeting co-stimulatory receptors into the gp96-Ig expression vector.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.